Richard S Nicholas1, Elijah E Rhone1, Alice Mariottini1, Eli Silber1, Omar Malik1, Victoria Singh-Curry1, Ben Turner1, Antonio Scalfari1, Olga Ciccarelli1, Maria P Sormani1, Eduardo Olavarria1, Varun Mehra1, Ian Gabriel1, Majid A Kazmi1, Paolo Muraro2. 1. From the Department of Brain Sciences (R.S.N., A.M., A.S., P.M.), Faculty of Medicine, and Centre for Haematology (E.O., I.G.), Faculty of Medicine, Imperial College London; Imperial College Healthcare NHS Trust (R.S.N., O.M., V.S.-C., A.S., E.O., I.G., P.M.); Department of Neurology (E.E.R., E.S.), King's College Hospital, London, UK; Department of Neurosciences, Drug and Child Health (A.M.), University of Florence, Italy; Barts Health NHS Trust (B.T.); Department of Haematological Medicine (V.M., M.A.K.), King's College Hospital NHS Foundation Trust; Queen Square MS Centre (O.C.), Department of Neuroinflammation, UCL Queen Square Institute of Neurology, London, UK; Department of Health Sciences (DISSAL) (M.P.S.), University of Genova; and IRCCS Ospedale Policlinico San Martino (M.P.S.), Genova, Italy. 2. From the Department of Brain Sciences (R.S.N., A.M., A.S., P.M.), Faculty of Medicine, and Centre for Haematology (E.O., I.G.), Faculty of Medicine, Imperial College London; Imperial College Healthcare NHS Trust (R.S.N., O.M., V.S.-C., A.S., E.O., I.G., P.M.); Department of Neurology (E.E.R., E.S.), King's College Hospital, London, UK; Department of Neurosciences, Drug and Child Health (A.M.), University of Florence, Italy; Barts Health NHS Trust (B.T.); Department of Haematological Medicine (V.M., M.A.K.), King's College Hospital NHS Foundation Trust; Queen Square MS Centre (O.C.), Department of Neuroinflammation, UCL Queen Square Institute of Neurology, London, UK; Department of Health Sciences (DISSAL) (M.P.S.), University of Genova; and IRCCS Ospedale Policlinico San Martino (M.P.S.), Genova, Italy. p.muraro@imperial.ac.uk.
Abstract
OBJECTIVE: To examine outcomes in people with multiple sclerosis (PwMS) treated with autologous hematopoietic stem cell transplantation (AHSCT) in a real-world setting. METHODS: This was a retrospective cohort study of PwMS treated with AHSCT at 2 centers in London, UK, consecutively between 2012 and 2019 who had ≥6 months of follow-up or died at any time. Primary outcomes were survival free of multiple sclerosis (MS) relapses, MRI new lesions, and worsening of Expanded Disability Status Scale (EDSS) score. Adverse events rates were also examined. RESULTS: The cohort includes 120 PwMS; 52% had progressive MS (primary or secondary) and 48% had relapsing-remitting MS. At baseline, the median EDSS score was 6.0; 90% of the evaluable cases showed MRI activity in the 12 months preceding AHSCT. Median follow-up after AHSCT was 21 months (range 6-85 months). MS relapse-free survival was 93% at 2 years and 87% at 4 years after AHSCT. No new MRI lesions were detected in 90% of participants at 2 years and in 85% at 4 years. EDSS score progression-free survival (PFS) was 75% at 2 years and 65% at 4 years. Epstein-Barr virus reactivation and monoclonal paraproteinemia were associated with worse PFS. There were 3 transplantation-related deaths within 100 days (2.5%), all after fluid overload and cardiac or respiratory failure. CONCLUSIONS: Efficacy outcomes of AHSCT in this real-world cohort are similar to those reported in more stringently selected clinical trial populations, although the risks may be higher. CLASSIFICATION OF EVIDENCE: This study is rated Class IV because of the uncontrolled, open-label design.
OBJECTIVE: To examine outcomes in people with multiple sclerosis (PwMS) treated with autologous hematopoietic stem cell transplantation (AHSCT) in a real-world setting. METHODS: This was a retrospective cohort study of PwMS treated with AHSCT at 2 centers in London, UK, consecutively between 2012 and 2019 who had ≥6 months of follow-up or died at any time. Primary outcomes were survival free of multiple sclerosis (MS) relapses, MRI new lesions, and worsening of Expanded Disability Status Scale (EDSS) score. Adverse events rates were also examined. RESULTS: The cohort includes 120 PwMS; 52% had progressive MS (primary or secondary) and 48% had relapsing-remitting MS. At baseline, the median EDSS score was 6.0; 90% of the evaluable cases showed MRI activity in the 12 months preceding AHSCT. Median follow-up after AHSCT was 21 months (range 6-85 months). MS relapse-free survival was 93% at 2 years and 87% at 4 years after AHSCT. No new MRI lesions were detected in 90% of participants at 2 years and in 85% at 4 years. EDSS score progression-free survival (PFS) was 75% at 2 years and 65% at 4 years. Epstein-Barr virus reactivation and monoclonal paraproteinemia were associated with worse PFS. There were 3 transplantation-related deaths within 100 days (2.5%), all after fluid overload and cardiac or respiratory failure. CONCLUSIONS: Efficacy outcomes of AHSCT in this real-world cohort are similar to those reported in more stringently selected clinical trial populations, although the risks may be higher. CLASSIFICATION OF EVIDENCE: This study is rated Class IV because of the uncontrolled, open-label design.
Authors: Richard K Burt; Roumen Balabanov; Xiaoqiang Han; Basil Sharrack; Amy Morgan; Kathleeen Quigley; Kim Yaung; Irene B Helenowski; Borko Jovanovic; Dzemila Spahovic; Indira Arnautovic; Daniel C Lee; Brandon C Benefield; Stephen Futterer; Maria Carolina Oliveira; Joachim Burman Journal: JAMA Date: 2015-01-20 Impact factor: 56.272
Authors: Richard K Burt; Bruce A Cohen; Eric Russell; Kenneth Spero; Akash Joshi; Yu Oyama; William J Karpus; Kehuan Luo; Borko Jovanovic; Ann Traynor; Karyn Karlin; Dusan Stefoski; William H Burns Journal: Blood Date: 2003-07-03 Impact factor: 22.113
Authors: Harold L Atkins; Marjorie Bowman; David Allan; Grizel Anstee; Douglas L Arnold; Amit Bar-Or; Isabelle Bence-Bruckler; Paul Birch; Christopher Bredeson; Jacqueline Chen; Dean Fergusson; Mike Halpenny; Linda Hamelin; Lothar Huebsch; Brian Hutton; Pierre Laneuville; Yves Lapierre; Hyunwoo Lee; Lisa Martin; Sheryl McDiarmid; Paul O'Connor; Timothy Ramsay; Mitchell Sabloff; Lisa Walker; Mark S Freedman Journal: Lancet Date: 2016-06-09 Impact factor: 79.321
Authors: Chris H Polman; Stephen C Reingold; Brenda Banwell; Michel Clanet; Jeffrey A Cohen; Massimo Filippi; Kazuo Fujihara; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Fred D Lublin; Xavier Montalban; Paul O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Emmanuelle Waubant; Brian Weinshenker; Jerry S Wolinsky Journal: Ann Neurol Date: 2011-02 Impact factor: 10.422
Authors: Basil Sharrack; Riccardo Saccardi; Tobias Alexander; Manuela Badoglio; Joachim Burman; Dominique Farge; Raffaella Greco; Helen Jessop; Majid Kazmi; Kirill Kirgizov; Myriam Labopin; Gianluigi Mancardi; Roland Martin; John Moore; Paolo A Muraro; Montserrat Rovira; Maria Pia Sormani; John A Snowden Journal: Bone Marrow Transplant Date: 2019-09-26 Impact factor: 5.483
Authors: Maximilian Christopeit; Martin Schmidt-Hieber; Rosanne Sprute; Oliver A Cornely; Georg Maschmeyer; Dieter Buchheidt; Marcus Hentrich; Meinolf Karthaus; Olaf Penack; Markus Ruhnke; Florian Weissinger Journal: Ann Hematol Date: 2020-10-20 Impact factor: 3.673
Authors: Paolo A Muraro; Roland Martin; Giovanni Luigi Mancardi; Richard Nicholas; Maria Pia Sormani; Riccardo Saccardi Journal: Nat Rev Neurol Date: 2017-06-16 Impact factor: 42.937
Authors: Maria Teresa Cencioni; Angela Genchi; Gavin Brittain; Thushan I de Silva; Basil Sharrack; John Andrew Snowden; Tobias Alexander; Raffaella Greco; Paolo A Muraro Journal: Front Immunol Date: 2022-02-01 Impact factor: 7.561
Authors: Valentin von Niederhäusern; Josefine Ruder; Marie Ghraichy; Ilijas Jelcic; Antonia Maria Müller; Urs Schanz; Roland Martin; Johannes Trück Journal: Neurol Neuroimmunol Neuroinflamm Date: 2022-10-13